Divergent Fortunes For Japan Firms’ Recent U.S. Approvals?
This article was originally published in PharmAsia News
Executive Summary
Recent product approvals in the U.S have included major milestones for two Japanese companies and their U.S. alliance partners. But commercial prospects for the two very different drugs are seen varying widely.